DII235 / Argo Biopharma, Novartis - LARVOL DELTA

Argo Biopharmaceutical…announced that the first patient has been dosed in a global Phase 2b clinical trial sponsored by Novartis evaluating DII235, also known as BW-20829, in adults with elevated Lipoprotein (a) (Lp(a)) and Atherosclerotic Cardiovascular Disease (ASCVD) (PRNewswire) - "In connection with the molecule's advancement into Phase 2b under its exclusive license and collaboration agreement with Novartis, Argo Biopharma will receive milestone payments that will support ongoing research and development efforts across its hepatic and extra-hepatic siRNA portfolio."

Financing • Trial status • Cardiovascular

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=64 | Completed | Sponsor: Argo Biopharma Australia Pty Ltd | Suspended ➔ Completed

Trial completion

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=64 | Suspended | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Suspended

Trial suspension

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=64 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | N=40 ➔ 64

Enrollment change

A study to evaluate the safety of BW-20829 in subjects with elevated lipoprotein(a) (ANZCTR) - P1 | N=40 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023

Enrollment open • Trial initiation date